ImmunityBio Director Cheryl Cohen sells shares under 10b5-1 plan
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Director Cheryl Cohen sold 81,056 shares of ImmunityBio stock on October 2, 2026, for a total value of $851,088.00. The transaction was disclosed in a filing with the SEC and was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Cohen directly owned 100,309 shares.
From tickerreport.com
Why it matters
The sale occurred while ImmunityBio recently reported revenue of $51.24 million, surpassing consensus estimates, although the company posted ($0.22) earnings per share. The transaction was disclosed to the SEC.
From tickerreport.com
Who's involved
- Cheryl CohenDirector who sold 81,056 shares of ImmunityBio stock
- ImmunityBioBiotech company whose shares were sold
- SECRegulatory body to which the transaction was filed